bluuebunny/crossref_metadata_2025_split huggingface dataset:
A review of air filter test standards for particulate matter of general ventilation
Authors: Yit Jing Ee , Chew Bee Teng , Yau Yat Huang 
Published: April 2020

Air filters play an important role in a heating, ventilation and air-conditioning (HVAC) system to maintain good indoor air quality of a building. The air filter test standards act as a guideline to evaluate the air filter performance. The current global test standard, ISO 16890:2016 adopts particulate matter classification which can be easily understood. The European standard, EN 779:2012 is obsolete and replaced by ISO 16890:2016 in June 2018. ASHRAE 52.2:2017 which adopts the minimum efficiency reporting value (MERV) classification is still widely used in the United States. Some countries in Southeast Asia such as Malaysia, Brunei and Singapore are applying different standards: EN779, ASHRAE 52.2 and ISO 16890. A standardization of the air filter testing and classification is undoubtedly important in the global air filtration market. This paper can act as a reference and assist these developing countries in adopting the suitable air filter testing standard to develop their national standard. As all three standards have no specifications on energy efficiency classification, the energy rating system can be obtained using Eurovent 4/21-2018. The HVAC-system-supplied air quality can be further improved with the consideration of WHO annual mean pollutant limits and EN 16798-3 air classification to determine the supply air cleanliness. Practical application: Although EN 779 is replaced by ISO 16890, some developing countries are still in the transition period. Manufacturers and consumers apply different standards which are EN 779, ASHRAE 52.2 and ISO 16890; therefore, a global filter testing standardization is important. This paper can act as a reference and assist the countries in other regions especially in Southeast Asia to develop respective national standard. Besides, some recommendations are given to improve the air filtration and ventilation system by referring to the WHO guidelines for the air pollutant limits, EN 16798-3 for the supply air quality and Eurovent 4/21 for the air filter energy rating.
Use of Complementary and Alternative Medicine in Children With Tourette Syndrome
Authors: Patel Himadri , Nguyen KieuHanh , Lehman Erik , Mainali Gayatra , Duda Laura , Byler Debra , Kumar Ashutosh 
Published: April 2020

Introduction: Tourette syndrome is a neuropsychiatric condition defined by motor and phonic tics with onset in childhood. Many families have concerns regarding potential side effects of pharmacologic treatments, and often have difficulty accessing comprehensive behavioral intervention for tics. Patients and caregivers may turn to complementary and alternative medicine (CAM) as they perceive these as “natural” and therefore “safe.” Although there are anecdotal reports of an increased use of CAM in Tourette syndrome patients, the exact prevalence is unknown. Objective: The purpose of this study was to identify commonly used CAM therapies for children with Tourette syndrome at Penn State Hershey Medical Center. Methods: A questionnaire was administered to the caregivers of children (<18 years old) via telephone. The data pertaining to demographics, type of CAM use, duration of use, adverse effects, and caregiver’s perception of the effectiveness were collected. Results: A total of 110 patients participated in this survey. When inquired about the different CAM methods, 69.1% of the participants reported using 1 or more CAM therapies, and 58% of those who used CAM informed the doctor about their use. Ninety-three percent of those who used CAM therapy reported a decrease in tic frequency. The most commonly used CAM therapies were stress management (44.6%), herbal medicine (18.2%), homeopathy (12.7%), and meditation (9.1%). In total, 46% of the participants said that CAM helped more than medication. Conclusion: The majority of patients interviewed were using CAM therapies, and a significant portion reported benefit greater than medication. More than half of all participants discussed CAM therapies with their physicians, and 63% of participants felt that their physicians would support their use of CAM therapies.
Comparison of Low- Versus High-Dose Four-Factor Prothrombin Complex Concentrate (4F-PCC) for Factor Xa Inhibitor–Associated Bleeding: A Retrospective Study
Authors: Wilsey H Andrew , Bailey Abby M. , Schadler Aric , Davis George A. , Nestor Melissa , Pandya Komal 
Published: April 2020

Background: Although andexanet alfa was recently approved as a specific reversal agent for apixaban and rivaroxaban, some providers still elect to administer 4-factor prothrombin complex concentrate (4F-PCC) instead, due to concerns surrounding efficacy, thrombotic risk, administration logistics, availability, and cost. Previous studies have described success with 4F-PCC doses ranging from 25 to 35 U/kg, with some guidelines recommending 50 U/kg. Objectives: The purpose of this study was to compare hemostasis between patients receiving low- (20-34 U/kg) versus high-dose (35-50 U/kg) 4F-PCC for the urgent reversal of apixaban and rivaroxaban. Patients/Methods: We performed a retrospective cohort study at a level one trauma center and comprehensive stroke center between January 2015 and December 2018. Main exclusion criteria included patients receiving less than 20 U/kg or if postreversal imaging were unavailable. Outcomes assessed included hemostasis for critical bleeding associated with apixaban or rivaroxaban and postoperative bleeding for reversal for emergent procedures. Results: The low-dose strategy was administered to n = 57 (57.6%) patients at a mean dose of 26.6 U/kg. The high-dose strategy was used in n = 42 (42.4%) patients at a mean dose of 47.6 U/kg. There was no difference in hemostasis by dosing strategy (75.4% vs 78.6%, P = .715) or hospital mortality (19.3% vs 35.7%, P = .067). No difference was found for secondary end points, including thrombotic events (5.3% vs 2.4%, P = .635) and hospital length of stay (11.3 vs 12.5 days, P = .070). Conclusions: Our comparison addresses a gap in the literature surrounding optimal dosing and supports a similar efficacy profile between dosing low- versus high-dose treatment.
Capital Accrual and Constraints: Domestic Sex Trafficking Victims’ Negotiation of Vicarious and Feminized Capital
Authors: Thorburn Natalie , Beddoe Liz 
Published: April 2020

Domestic sex trafficking has yet to appear on the policy agenda in Aotearoa New Zealand, and yet to be met with a law enforcement response. Accordingly, we have minimal knowledge about the contexts in which sex trafficking is perpetrated and what victims’ experiences involve. This article focuses specifically on the attainment and negotiation of social capital by victims whose access to traditional capital is at least partially restricted by their social and familial contexts. Sixteen victims of domestic sex trafficking participated in semistructured interviews. The data were analyzed using an adapted version of Clanindin and Connelly’s (2000) three-dimensional structure of narrative analysis. Three of the themes emerging from this are discussed here; namely abuse and mistreatment in early life, the negotiation of survival within the trafficking context, and sexuality as a bargaining tool. We argue that victims’ access to traditional mechanisms of social capital accrual may be precluded by the multiple sites of gendered disadvantage that collude to entrap victims in a subordinate and exploited position. However, to negotiate their continued survival despite the constraints to their agency, they appear to access both vicarious physical capital and feminized (and usually sexualised) capital by instrumentalizing their sexual appeal or prowess and the protection of the subjectively more powerful male “partner.”
Healthcare supply chain management: Application in the Maltese Healthcare System
Authors: Buttigieg Sandra C , Bezzina Frank , Xuereb Andrew , Dey Prasanta K 
Published: April 2020

Introduction Hospital supply chains are complex systems ensuring flow of products/services to satisfy patients. The aim of this exploratory study is to improve the Maltese health care system’s efficiency using supply chain management principles in three hospital settings. The theoretical basis underlying the study is the supply chain decision-making framework. Methods Using observation and focus groups, the following steps were undertaken: (i) mapping healthcare supply chain processes and identifying challenges; (ii) understanding competitive strategy through implied demand uncertainty; (iii) deriving supply chain strategies through supply chain drivers; (iv) optimizing healthcare supply chain (right balance between cost and responsiveness); (v) identifying critical success factors for healthcare supply chains. Results In line with their competitive and supply chain strategies, the three settings have well-defined primary goals, stakeholders’ needs/demands/expectations, as well as clear-cut, albeit some similar, criteria and sub-criteria for improving the quality and quantity of their services. The trade-offs between efficiency and responsiveness for the supply chain drivers are distinctive and in line with their competitive strategies, hence achieving the desired fit with the healthcare supply chain strategies. Conclusions By adopting healthcare supply chain principles, there should be improved services in each setting, which in turn should lead to system-wide results.
An Integrative Review of the Role of Palliative Care in Lung Transplantation
Authors: Pawlow Patricia C. , Doherty Caroline L. , Blumenthal Nancy P. , Matura Lea Ann , Christie Jason D. , Ersek Mary 
Published: April 2020

Background: Lung transplant patients experience significant physical symptoms and psychological stress that affect their quality of life. Palliative care is an interdisciplinary specialty associated with improved symptom management and enhanced quality of life. Little, however, is known about the palliative care needs of lung transplant patients and the role it plays in their care. Aim: The aim of this integrative review was to synthesize the literature describing the palliative care needs, the current role, and factors influencing the integration of palliative care in the care of lung transplant patients. Design/Data Sources: We searched PubMed, Scopus, CINAHL, and Embase to identify English-language, primary studies focused on palliative care in adult lung transplantation. Study quality was evaluated using Strengthening the Report of Observational studies in Epidemiology and Consolidated Criteria for Reporting Qualitative Research criteria. Results: Seven articles were included in the review. Most were single-center, descriptive studies. Two studies used qualitative and 5 used quantitative methodologies. Collectively, these studies suggest that palliative care is typically consulted for physical and psychological symptom management, although consultation is uncommon and often occurs late in the lung transplant process. We found no studies that systematically assessed palliative needs. Misperceptions about palliative care, communication challenges, and unrealistic patient/family expectations are identified barriers to the integration. While limited, evidence suggests that palliative care can be successfully integrated into lung transplant patient management. Conclusions: Empirical literature about palliative care in lung transplantation is sparse. Further research is needed to define the needs and opportunities for integration into the care of these patients.
MicroRNA-429/Cxcl1 Axis Protective Against Oxygen Glucose Deprivation/Reoxygenation-Induced Injury in Brain Microvascular Endothelial Cells
Authors: Leng Jun , Liu Wei , Li Li , Wei Fang Yue , Tian Meng , Liu Hui Min , Guo Wen 
Published: April 2020

Objective:The objective of the present work was to study the role of Cxcl1 in cerebral ischemia–reperfusion (I/R) injury and to in-depth explore its pathogenesis.Methods:The expression of Cxcl1 based on the public data was analyzed. Then, we constructed an oxygen glucose deprivation/reoxygenation (OGD/R) model in vitro using mice brain microvascular endothelial cells (BMECs) to simulate cerebral I/R in vivo.Results:The results of quantitative real-time polymerase chain reaction assay uncovered that Cxcl1 showed higher expression while miR-429 showed lower expression in BMECs damaged by OGD/R, whereas overexpression of Cxcl1 or inhibition of miR-429 expression can strengthen this effect. Hereafter, through dual luciferase reporter assay, we verified that miR-429 directly targets Cxcl1 and negatively regulates Cxcl1 expression. Furthermore, the results also revealed that overexpression of Cxcl1 can reverse the miR-429-mediated effects.Conclusion:We concluded that miR-429 exerts protective effects against OGD/R-induce injury in vitro through modulation of Cxcl1 and nuclear factor kinase B pathway, hoping provide a new view on the pathogenesis of cerebral I/R injury and a feasible potential therapeutic target.
Lessons learned in practice-based research: Studying language interventions for young children in the real world
Authors: Smyth Rachael E , Theurer Julie , Archibald Lisa MD , Oram Cardy Janis 
Published: April 2020

Background and aims Practice-based research holds potential as a promising solution to closing the research-practice gap, because it addresses research questions based on problems that arise in clinical practice and tests whether systems and interventions are effective and sustainable in a clinical setting. One type of practice-based research involves capturing practice by collecting evidence within clinical settings to evaluate the effectiveness of current practices. Here, we describe our collaboration between researchers and clinicians that sought to answer clinician-driven questions about community-based language interventions for young children (Are our interventions effective? What predicts response to our interventions?) and to address questions about the characteristics, strengths, and challenges of engaging in practice-based research. Methods We performed a retrospective chart review of 59 young children who had participated in three group language interventions at one publicly funded community clinic between 2012 and 2017. Change on the Focus on the Outcomes of Communication Under Six (FOCUS), a government mandated communicative participation measure, was extracted as the main outcome measure. Potential predictors of growth during intervention were also extracted from the charts, including type of intervention received, attendance, age at the start of intervention, functional communication ability pre-intervention, and time between pre- and post-intervention FOCUS scores. Results Overall, 49% of children demonstrated meaningful clinical change on the FOCUS after their participation in the language groups. Only 3% of participants showed possibly meaningful clinical change, while the remaining 46% of participants demonstrated not likely meaningful clinical change. There were no significant predictors of communicative participation growth during intervention. Conclusions Using a practice-based research approach aimed at capturing current practice, we were able to answer questions about the effectiveness of interventions delivered in real-world settings and learn about factors that do not appear to influence growth during these interventions. We also learned about benefits associated with engaging in practice-based research, including high clinical motivation, high external validity, and minimal time/cost investment. Challenges identified were helpful in informing our future efforts to examine other possible predictors through development of a new, clinically feasible checklist, and to pursue methods for improving collection of outcome data in the clinical setting. Implications: Clinicians and researchers can successfully collaborate to answer clinically informed research questions while considering realistic clinical practice and using research-informed methods and principles. Practice-based research partnerships between researchers and clinicians are both valuable and feasible.
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA
Authors: Palladini Giovanni , Kastritis Efstathios , Maurer Mathew S. , Zonder Jeffrey , Minnema Monique C. , Wechalekar Ashutosh D. , Jaccard Arnaud , Lee Hans C. , Bumma Naresh , Kaufman Jonathan L. , Medvedova Eva , Kovacsovics Tibor , Rosenzweig Michael , Sanchorawala Vaishali , Qin Xiang , Vasey Sandra Y. , Weiss Brendan M. , Vermeulen Jessica , Merlini Giampaolo , Comenzo Raymond L. 
Published: April 2020

Abstract
Although no therapies are approved for light chain (AL) amyloidosis, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) is considered standard of care. Based on outcomes of daratumumab in multiple myeloma (MM), the phase 3 ANDROMEDA study (NCT03201965) is evaluating daratumumab-CyBorD vs CyBorD in newly diagnosed AL amyloidosis. We report results of the 28-patient safety run-in. Patients received subcutaneous daratumumab (DARA SC) weekly in cycles 1 to 2, every 2 weeks in cycles 3 to 6, and every 4 weeks thereafter for up to 2 years. CyBorD was given weekly for 6 cycles. Patients had a median of 2 involved organs (kidney, 68%; cardiac, 61%). Patients received a median of 16 (range, 1-23) treatment cycles. Treatment-emergent adverse events were consistent with DARA SC in MM and CyBorD. Infusion-related reactions occurred in 1 patient (grade 1). No grade 5 treatment-emergent adverse events occurred; 5 patients died, including 3 after transplant. Overall hematologic response rate was 96%, with a complete hematologic response in 15 (54%) patients; at least partial response occurred in 20, 22, and 17 patients at 1, 3, and 6 months, respectively. Renal response occurred in 6 of 16, 7 of 15, and 10 of 15 patients, and cardiac response occurred in 6 of 16, 6 of 13, and 8 of 13 patients at 3, 6, and 12 months, respectively. Hepatic response occurred in 2 of 3 patients at 12 months. Daratumumab-CyBorD was well tolerated, with no new safety concerns versus the intravenous formulation, and demonstrated robust hematologic and organ responses. This trial was registered at www.clinicaltrials.gov as #NCT03201965.
A Group of Complexes Based on PAMAM and Quantum Dots Used in Clinical Immunoassays
Authors: Liu Yang , Hou Lu , Guo Qiong , Zhang Mingjin , Shi Wei 
Published: April 2020

AbstractWe report a group of complexes used in clinical immunoassays. The complexes include a PAMAM-conjugated goat anti-rabbit IgG and a QDs-conjugated goat anti-mouse IgG. When rabbit anti-antigen and mouse anti-antigen are added, the corresponding antigen will be detected. The experiment, using the complexes, is simple, convenient, short in time, and short in steps. It is also applicable to different experiment methods, like to be used with FCM (flow cytometry), ICC (immunocytochemistry), and IHC (immunohistochemistry) to detect many kinds of antigens.
GMO regulations and their interpretation: how EFSA’s guidance on risk assessments of GMOs is bound to fail
Authors: Hilbeck Angelika , Meyer Hartmut , Wynne Brian , Millstone Erik 
Published: April 2020

AbstractWe identify the origins, and key characteristics, of the current regulatory framework for genetically modified organisms (GMOs) in the European Union (EU). We focus on the approach of the European Food Safety Authority (EFSA) to assessing GMO risks to public and environmental health. An historical account informs our critical appraisal of the current practices of EFSA’s GMO panel, and helps to explain how and why it fails to satisfy the objectives of the EU’s GMO legislation. While those legislative texts set appropriate objectives, their concrete implementation has fallen far short of the legislative goals. EFSA’s prevailing approach to GM crop and food risk assessment starts from what it terms a ‘comparative safety assessment’. Those comparisons require the scrutiny of sets of molecular, chemical and phenotypic data from GM plants and non-GM varieties (many of which may be only remotely related to the GM variety). Those data are, however, inadequate for predicting adverse biological, toxicological and ecological effects. EFSA’s ‘comparative safety assessments’ draw over-optimistic conclusions from too little data from too few studies. When GM products are deemed to have passed a ‘comparative safety assessment’, EFSA has interpreted that as grounds for conducting only very narrowly circumscribed risk assessments, which have not required meaningful data from studies of ecological or eco-toxicological impacts. This is a reductionist approach to risk assessment, when a more inclusive and comprehensive approach, which we outline, is scientifically available, and also more likely to meet the specified legislative aims. Instead, however, the reductionist choice is systematically applied, but never justified nor acknowledged as such. Indeed, it is concealed, by EFSA and by its main policy client the European Commission, as if it were only for specialist expert scientific deliberation. Thus, key questions that sound scientific assessments should ask about potential harm are not even posed, let alone answered—or at least, they are ‘answered’ only by default, given that the implicit burden of proof requires harm to be demonstrated. Furthermore, and a key point of this paper, we show how the problematic features of EFSA’s approach have been premised on a set of evaluative policy judgements, rather than purely scientific considerations. Responsibility for selecting how EFSA frames its scientific approach should however lie with European Commission risk managers, and not with EFSA. These problems might have been and could be avoided if explicit commitments entered into by the EU at the Codex Alimentarius Commission were implemented by the European Commission and EFSA were instructed accordingly.
pyCancerSig: subclassifying human cancer with comprehensive single nucleotide, structural and microsatellite mutational signature deconstruction from whole genome sequencing
Authors: Thutkawkorapin Jessada , Eisfeldt Jesper , Tham Emma , Nilsson Daniel 
Published: April 2020

Abstract
Background
DNA damage accumulates over the course of cancer development. The often-substantial amount of somatic mutations in cancer poses a challenge to traditional methods to characterize tumors based on driver mutations. However, advances in machine learning technology can take advantage of this substantial amount of data.

Results
We developed a command line interface python package, pyCancerSig, to perform sample profiling by integrating single nucleotide variation (SNV), structural variation (SV) and microsatellite instability (MSI) profiles into a unified profile. It also provides a command to decipher underlying cancer processes, employing an unsupervised learning technique, Non-negative Matrix Factorization, and a command to visualize the results. The package accepts common standard file formats (vcf, bam). The program was evaluated using a cohort of breast- and colorectal cancer from The Cancer Genome Atlas project (TCGA). The result showed that by integrating multiple mutations modes, the tool can correctly identify cases with known clear mutational signatures and can strengthen signatures in cases with unclear signal from an SNV-only profile. The software package is available at https://github.com/jessada/pyCancerSig.

Conclusions
pyCancerSig has demonstrated its capability in identifying known and unknown cancer processes, and at the same time, illuminates the association within and between the mutation modes.